286 related articles for article (PubMed ID: 37011983)
1. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
[No Abstract] [Full Text] [Related]
2. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
3. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
4. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic significance of DEK-NUP214 fusion gene in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Gao MG; Fu Q; Qin YZ; Chang YJ; Wang Y; Yan CH; Xu LP; Zhang XH; Huang XJ; Zhao XS
Zhonghua Nei Ke Za Zhi; 2021 Oct; 60(10):868-874. PubMed ID: 34551474
[No Abstract] [Full Text] [Related]
6. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.
Fang H; Yabe M; Zhang X; Kim Y; Wu X; Wei P; Chi S; Zheng L; Garcia-Manero G; Shao L; Yuan J; Shen Y; Zheng G; Tang G; Wang W; Loghavi S; Shen Q; Yuan Y; He R; Chen D; Medeiros LJ; Hu S
Mod Pathol; 2021 Jun; 34(6):1143-1152. PubMed ID: 33558656
[TBL] [Abstract][Full Text] [Related]
7. Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive acute myeloid leukemia: a case report.
Zhang X; Zhang X
Ann Palliat Med; 2021 Apr; 10(4):4955-4958. PubMed ID: 33832283
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
[No Abstract] [Full Text] [Related]
9. Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism.
Wang F; Xie M; Chen P; Wang D; Yang M
Oxid Med Cell Longev; 2022; 2022():8212286. PubMed ID: 35873796
[TBL] [Abstract][Full Text] [Related]
10. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.
Sandahl JD; Coenen EA; Forestier E; Harbott J; Johansson B; Kerndrup G; Adachi S; Auvrignon A; Beverloo HB; Cayuela JM; Chilton L; Fornerod M; de Haas V; Harrison CJ; Inaba H; Kaspers GJ; Liang DC; Locatelli F; Masetti R; Perot C; Raimondi SC; Reinhardt K; Tomizawa D; von Neuhoff N; Zecca M; Zwaan CM; van den Heuvel-Eibrink MM; Hasle H
Haematologica; 2014 May; 99(5):865-72. PubMed ID: 24441146
[TBL] [Abstract][Full Text] [Related]
11. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
12. [Outcomes of adult patients with
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
[No Abstract] [Full Text] [Related]
13. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
[TBL] [Abstract][Full Text] [Related]
17. Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
Zhang Y; Li X; Weng X; Shen Y; Chen Y; Zheng Y; Zhao H; You J; Mao Y; Wang L; Wu M; Sheng Y; Wu J; Hu J; Chen Q; Li J
Am J Hematol; 2022 Jan; 97(1):43-51. PubMed ID: 34687467
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen].
Wang J; Jiang B; Jiang Q; Lu J; Zhu HH; Yang SM; Zhao T; Wen L; Bao L; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):194-200. PubMed ID: 27033755
[TBL] [Abstract][Full Text] [Related]
20. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
